| With hundreds of billions of dollars in the mix, some M&A deals are bound to fall flat. Many have helped put cutting-edge treatments in the hands of patients—as well as cash cows in the hands of drugmakers—but others have led to layoffs, legal headaches, and lab and site closures, as well as antitrust reviews, spooked investors and staggering amounts of debt. In our special report, we’ve compiled the 15 biggest misfires of the decade. They range in size and structure, but there’s no doubt they reshaped swaths of the industry, for good or ill. | |
|
Featured Story | | | Monday, December 2, 2019 Baird analyst Brian Skorney has dismissed the chances of Biogen winning approval for its Alzheimer’s disease drug aducanumab. Skorney’s skeptical reading comes days before Biogen is due to discuss data from its phase 3 program at the Clinical Trials on Alzheimer’s Disease annual congress. |
|
|---|
|
Top Stories Of The Week While many of the decade's M&A deals worked out for the buyers, others didn't deliver on their promises. Here, we feature 15 of those deals, including Bayer's Monsanto buy, Teva's purchase of Allergan's generics, AbbVie's Synageva pickup and many others. Monday, December 2, 2019 It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage in the world’s second largest pharmaceutical market. AbbVie, AstraZeneca and Bayer are among multinational companies to have reached deals with the Chinese government to include steeply discounted drugs in the country’s insurance scheme. Wednesday, December 4, 2019 Not long after announcing a wide-ranging partnership with Microsoft to bring artificial intelligence tools to every desk across its R&D departments, Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations. Monday, December 2, 2019 In this week's FiercePharmaPolitics, an analyst outlines how current drug pricing proposals would affect the industry, plus more. Some proposals would bring modest disruption to drug companies, but House speaker Nancy Pelosi's plan would bring a “fundamental change of business model," he wrote. Tuesday, December 3, 2019 Astellas Pharma is set to buy Audentes Therapeutics for $3 billion. The deal will enable Astellas to set up a new genetic regulation unit spearheaded by a neuromuscular disease gene therapy that is set to be submitted for approval next year. Tuesday, December 3, 2019 In its final days as an independent company, Celgene scored a win last month with the FDA's approval of rare blood disease med Reblozyl—a potential blockbuster in some analysts' eyes. Now, the FDA wants a closer look at Reblozyl as a treatment for a group of rare blood cancers. Monday, December 2, 2019 A team at Brigham and Women's Hospital discovered a microRNA in the microbiome that increases when multiple sclerosis peaks. When they gave a synthetic version of the microRNA to mice as an oral treatment, it suppressed symptoms of the disease. Tuesday, December 3, 2019 Merck & Co.'s Keytruda could be the first PD-1/L1 inhibitor to enter the untapped non-muscle invasive bladder cancer realm thanks to an FDA priority review. However, a gene therapy has nabbed the same designation for the same setting, with phase 3 data expected this week. Monday, December 2, 2019 John Ratliff’s position has changed three times this fall, but now, much like the falling leaves, he looks to have settled. Monday, December 2, 2019 Novartis' big push into cell and gene therapy hasn't been the smoothest of rides, with a data manipulation scandal hamstringing Zolgensma and manufacturing concerns hurting CAR-T cancer therapy Kymriah. Could a new European facility help turn around the latter's production bottleneck? Enrollment Showcase | | | Sponsored by: University of Florida College of Pharmacy University of Florida precision medicine leaders highlight current knowledge and trends to advance the future of health care in this new webinar series. Register today. |
|
|---|
|
Resources Sponsored by: Clarivate Analytics Get your copy of the Q2 2019 Life Sciences M&A notes and trends to understand the mergers and acquisitions (M&A) activity in the life sciences sector which drove 136 new M&A deals and provides a forward look to 2020 activity ahead. Sponsored by: Thermo Fisher Scientific Are you facing costly delays in your API scale-up? Sponsored by: Roche and IQVIA This global landscape study identifies and assesses innovative funding models for cancer and other high-cost chronic NCDs across Africa, Asia, Europe, Latin America and Middle East. The study aims to enable readers to better understand the possibilities that innovative funding models bring to bridge the current and future funding gap, while stressing the key success factors that enable sustainability and success such as stakeholder collaboration. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 